Premium
Cellular GABAergic Neuroactive Steroid (3α,5α)‐3‐Hydroxy‐Pregnan‐20‐One (3α,5α‐THP) Immunostaining Levels Are Increased in the Ventral Tegmental Area of Human Alcohol Use Disorder Patients: A Postmortem Study
Author(s) -
Hasirci Ahmet Sait,
MaldonadoDevincci Antoniette M.,
Beattie Matthew C.,
O'Buckley Todd K.,
Morrow A. Leslie
Publication year - 2017
Publication title -
alcoholism: clinical and experimental research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 153
eISSN - 1530-0277
pISSN - 0145-6008
DOI - 10.1111/acer.13300
Subject(s) - ventral tegmental area , neuroactive steroid , gabaergic , allopregnanolone , medicine , endocrinology , alcohol use disorder , immunostaining , human brain , immunohistochemistry , substantia nigra , amygdala , hippocampus , pathology , biology , gabaa receptor , alcohol , dopamine , psychiatry , receptor , biochemistry , dopaminergic
Background The GABAergic neuroactive steroid (3α,5α)‐3‐hydroxy‐pregnan‐20‐one (3α,5α‐THP; allopregnanolone) enhances GABAergic activity and produces subjective effects similar to ethanol (EtOH). The effect of chronic alcohol exposure on 3α,5α‐THP concentrations has been studied in mouse, rat, and monkey limbic brain areas. Chronic EtOH exposure produced divergent brain region and cell‐specific changes in 3α,5α‐THP concentrations in animal studies. However, 3α,5α‐THP levels in similar human brain regions have never been examined in individuals diagnosed with alcohol use disorder (AUD). Therefore, we used immunohistochemistry (IHC) to examine 3α,5α‐THP levels in the ventral tegmental area (VTA), substantia nigra pars medialis (SNM), and amygdala of human postmortem brains of patients diagnosed with AUD compared with social drinkers. The effects of sex and liver disease on 3α,5α‐THP concentrations were examined in the aforementioned brain regions. Methods Human postmortem brains of AUD patients and age‐matched controls were obtained from the New South Wales Brain Tissue Resource Center. IHC was performed using anti‐3α,5α‐THP antibody on formalin‐fixed paraffin‐embedded brain sections to detect cellular 3α,5α‐THP levels. Immunoreactivity was analyzed by pixel density/mm 2 for the comparison between AUD patients and controls. Results 3α,5α‐THP immunoreactivity was increased by 23.2 ± 9% in the VTA of AUD patients compared with age‐matched controls ( p = 0.014). Moreover, a 29.6 ± 10% increase in 3α,5α‐THP immunoreactivity was observed in the SNM of male AUD patients compared with male controls ( p < 0.01), but not in female subjects. 3α,5α‐THP immunoreactivity in the VTA and SNM regions did not differ between noncirrhotic and cirrhotic AUD patients. A sex difference in 3α,5α‐THP immunoreactivity (female 51 ± 18% greater than male) was observed among control subjects in the SNM, but no other brain region. 3α,5α‐THP immunoreactivity in the basolateral amygdala and lateral amygdala was negatively correlated with the length of the tissue fixation time as well as the age of the subjects, precluding assessment of the effect of AUD. Conclusions Cellular 3α,5α‐THP levels in VTA are increased in human AUD patients, an effect that is likely independent of sex and liver disease. The differences between animal models and human studies should be factored into the interpretation of the physiological significance of elevated 3α,5α‐THP levels in humans.